Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report)'s stock price was up 21.8% on Tuesday . The company traded as high as $0.49 and last traded at $0.50. Approximately 48,603,004 shares changed hands during trading, a decline of 43% from the average daily volume of 85,729,586 shares. The stock had previously closed at $0.41.
Analyst Ratings Changes
Separately, StockNews.com started coverage on shares of Tonix Pharmaceuticals in a report on Saturday, January 25th. They issued a "hold" rating on the stock.
Check Out Our Latest Report on Tonix Pharmaceuticals
Tonix Pharmaceuticals Trading Up 14.1 %
The stock has a market capitalization of $79.99 million, a price-to-earnings ratio of -0.01 and a beta of 2.02. The firm has a 50-day moving average of $0.30 and a 200 day moving average of $0.28. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. As a group, equities analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.
Hedge Funds Weigh In On Tonix Pharmaceuticals
An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. PFG Investments LLC bought a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 218,003 shares of the company's stock, valued at approximately $72,000. PFG Investments LLC owned 0.12% of Tonix Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 82.26% of the company's stock.
Tonix Pharmaceuticals Company Profile
(
Get Free Report)
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Featured Stories
Before you consider Tonix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.
While Tonix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
